Skip to content
2000
Volume 16, Issue 1
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1) is a newly identified monooxygenase enzyme that is expressed specifically in tumor tissues and during fetal life. Particularly, high expression of CYP2W1 was observed in up to 60% of colorectal cancers and its expression correlated with poor survival. CYP2W1 has been shown to metabolize various endogenous substrates including lysophospholipids and several procarcinogens, such as polycyclic aromatic hydrocarbon. The specific substrate for CYP2W1, however, is currently unknown. Due to its tumor-specific expression and its unique catalytic activities in colorectal cancers, CYP2W1 was deemed as an interesting target in colorectal cancer therapy. This review sought to summarize the current understanding of the CYP2W1 biology and biochemistry, its genetic polymorphisms and cancer risk, and its implication as a tumor-specific diagnostic and therapeutic target.

Loading

Article metrics loading...

/content/journals/ccdt/10.2174/1568009616888151112095948
2016-01-01
2025-09-06
Loading full text...

Full text loading...

/content/journals/ccdt/10.2174/1568009616888151112095948
Loading

  • Article Type:
    Research Article
Keyword(s): Cancer therapeutics; colorectal cancer; CYP2W1; cytochrome P450; prodrug
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test